The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana

Background. Group A meningococcal disease occurs in large epidemics within the meningitis belt of Africa that includes northern Ghana. Major epidemics in the meningitis belt have infection rates ranging from 100 to 800 per 100 000 population. In 2012, a group A meningococcal conjugate vaccine, PsA-T...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2015-11, Vol.61 (suppl_5), p.S489-S492
Main Authors: Wak, George, Williams, John, Oduro, Abraham, Maure, Christine, Zuber, Patrick L. F., Black, Steven
Format: Article
Language:English
Subjects:
Adolescent
Adult
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - pathology
Epidemics
Female
Ghana - epidemiology
Humans
Infant, Newborn
Meningitis, Meningococcal - prevention & control
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - adverse effects
Middle Aged
Pregnancy
Pregnancy Complications, Infectious - prevention & control
Product Surveillance, Postmarketing
THE DEVELOPMENT, LICENSURE, AND INTRODUCTION OF MenAfriVac
The Meningitis Vaccine Project: The Development, Licensure, , and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Vaccines
Womens health
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Group A meningococcal disease occurs in large epidemics within the meningitis belt of Africa that includes northern Ghana. Major epidemics in the meningitis belt have infection rates ranging from 100 to 800 per 100 000 population. In 2012, a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), was introduced into the region in large campaigns. Methods. We report here on the safety of this vaccine when used in pregnant women in the Navrongo region of Ghana. Results. Rates of events in 1730 immunized pregnant women and their infants were compared to the rates of the same events in pregnant women who did not receive the vaccine during the campaign and also to women who were pregnant in the prior year. Conclusions. We found no evidence of any safety concerns when this vaccine was administered during pregnancy.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/civ625